Mediterr J Rheumatol 2016;27(2):81-4
A multicenter prospective registry of patients with Antiphosholipid Syndrome in Greece (The Greek APS registry)
Authors Information

Rheumatology Unit

First Department of Propaeudeutic and Internal Medicine, Joint Rheumatology Program School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece
  1. Miyakis S, Lockshin M D, Atsumi T, Branch D W, Brey R L, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
  2. Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. Lupus 2010;19:412-8.
  3. Cervera R, Piette J C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
  4. Cervera R, Serrano R, Pons-Estel G J, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al.; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011-8.
  5. Erkan D, Lockshin M D; APS ACTION members. APS ACTION - AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus 2012;21:695-8.
  6. Abreu M M, Danowski A, Wahl D G, Amigo M C, Tektonidou M, Pacheco M S, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14.
  7. Andrade D, Tektonidou M. Emerging therapies in Antiphospholipid Syndrome. Curr Rheumatol Rep 2016;18:22.
  8. Arnaud L, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015;14:192-200.
  9. Kampolis C, Tektonidou M, Moyssakis I, Tzelepis GE, Moutsopoulos H, Vlachoyiannopoulos P G. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum 2014;43:558-65.
  10. Tektonidou M G, Sotsiou F, Moutsopoulos H M. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 2008;35:1983-8.
  11. Cuadrado M J, Bertolaccini M L, Seed P T, Tektonidou M G, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 2014;53:275-84.
  12. Grika E P, Ziakas P D, Zintzaras E, Moutsopoulos H M, Vlachoyiannopoulos P G. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012;39:516-23.
  13. Cervera R, Tektonidou M G, Espinosa G, Cabral A R, González E B, Erkan D, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus. 2011;20:174-81.
  14. Ruiz-Irastorza G, Cuadrado M J, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206-18.
  15. Tektonidou M G, Ioannidis J P, Boki K A, Vlachoyiannopoulos P G, Moutsopoulos H M. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 2000;93:523-30.